Development of a potent, practical neo-antigen vaccines is currently a key objective of immuno-oncology. Oncolytic immunotherapy uniquely generates a potent, patient specific tumor neo-antigen vaccine directly in situ in the patient. Replimune aims to provide a highly potent 'universal' neo-antigen vaccine through it's approach.
Tumor selective virus replication kills tumors. This releases the full array of neo-antigens in an inflamed tumor environment. Both innate and adaptive immune responses are triggered. This provides systemic vaccination and systemic efficacy, and is highly synergistic with immune checkpoint blockade.